Full Press Release Details
WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today provided an update on its ongoing development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-associated lymphomas.
Computer-based selection of EBV peptides is currently underway as part of Tevogen’s preparation for a potential clinical trial using EBV-specific CTLs manufactured using the Company’s proprietary ExacTcell™ technology. ExacTcell enables precision-engineered T cells with a high degree of specificity and scalability. In parallel, Tevogen’s R&D laboratory has initiated confirmation studies to validate CTL responses to the selected viral peptides.
Tevogen Bio’s scientific and clinical teams are working closely with Tevogen.AI, the Company’s artificial intelligence initiative, to co-develop an advanced peptide selection strategy. This collaboration aims to accelerate the identification of immunologically active targets across the EBV genome and further strengthen Tevogen’s therapeutic precision.
“The mechanisms behind EBV-induced tumorigenesis, which includes the disruption of cellular pathways and the promotion of malignant growth by EBV proteins, have become increasingly clear in recent years,” said Neal Flomenberg, MD, Chief Scientific Officer of Tevogen Bio. “Targeting these proteins with highly specific CTLs presents an exciting research frontier and the potential for meaningful therapeutic breakthroughs in EBV-driven cancers.”
Tevogen Bio will continue to share updates as the EBV research progresses through its preclinical evaluation phase.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Tags
cytotoxic T lymphocyte
Artificial Intelligence
Intellectual Property
Research and development